TY - JOUR
T1 - High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma
AU - Anagnostou, Valsamo K.
AU - Bepler, Gerold
AU - Syrigos, Konstantinos N.
AU - Tanoue, Lynn
AU - Gettinger, Scott
AU - Homer, Robert J.
AU - Boffa, Daniel
AU - Detterbeck, Frank
AU - Rimm, David L.
PY - 2009/6/15
Y1 - 2009/6/15
N2 - Purpose: Mammalian target of rapamycin (mTOR) is a key kinase downstream of phosphoinositide 3-kinase (PI3K)/AKT predominantly involved in translational control in the presence of nutrients and energy. Despite the well known role of mTORi n carcinogenesis, its prognostic potential inlung cancer has not beeninvestigated.Here,we quantitatively assessedmTORprotein expression in two large data sets to investigate the impact ofmTORexpression on patient survival. Experimental Design: Automated quantitative analysis (AQUA), a fluorescent-based method for analysis of in situ protein expression, was used to assessmTORexpression in a training cohort of 167 lung cancer patients. An independent cohort of 235 lung cancer patients (from a second institution) was used for validation. Results: Tumors expressed mTOR in the cytoplasmin 56% and 50% of the cases in training and validation cohorts, respectively; mTORe xpression was not associated with standard clinical or pathologic characteristics. Patients with high mTORe xpression had a longer median overall survival comparedwith the lowexpressers (52.7 versus 38.5months; log rank P = 0.06), whichwas more prominent in the adenocarcinoma group (55.7 versus 38.88 months; log rank P = 0.018). Multivariate analysis revealed an independent lower risk of death for adenocarcinoma and adenocarcinoma stage IA patients with mTOR-expressing tumors (hazard ratio, 0.48; 95% confidence interval, 0.24-0.98; P = 0.04, and hazard ratio, 0.12; 95% confidence interval, 0.03-0.72; P = 0.019, respectively). Conclusions: mTORex pression defines a subgroup of patients with a favorable outcome and may be useful for prognostic stratification of lung adenocarcinoma patients as well as incorporation of mTORin to clinical decisions.
AB - Purpose: Mammalian target of rapamycin (mTOR) is a key kinase downstream of phosphoinositide 3-kinase (PI3K)/AKT predominantly involved in translational control in the presence of nutrients and energy. Despite the well known role of mTORi n carcinogenesis, its prognostic potential inlung cancer has not beeninvestigated.Here,we quantitatively assessedmTORprotein expression in two large data sets to investigate the impact ofmTORexpression on patient survival. Experimental Design: Automated quantitative analysis (AQUA), a fluorescent-based method for analysis of in situ protein expression, was used to assessmTORexpression in a training cohort of 167 lung cancer patients. An independent cohort of 235 lung cancer patients (from a second institution) was used for validation. Results: Tumors expressed mTOR in the cytoplasmin 56% and 50% of the cases in training and validation cohorts, respectively; mTORe xpression was not associated with standard clinical or pathologic characteristics. Patients with high mTORe xpression had a longer median overall survival comparedwith the lowexpressers (52.7 versus 38.5months; log rank P = 0.06), whichwas more prominent in the adenocarcinoma group (55.7 versus 38.88 months; log rank P = 0.018). Multivariate analysis revealed an independent lower risk of death for adenocarcinoma and adenocarcinoma stage IA patients with mTOR-expressing tumors (hazard ratio, 0.48; 95% confidence interval, 0.24-0.98; P = 0.04, and hazard ratio, 0.12; 95% confidence interval, 0.03-0.72; P = 0.019, respectively). Conclusions: mTORex pression defines a subgroup of patients with a favorable outcome and may be useful for prognostic stratification of lung adenocarcinoma patients as well as incorporation of mTORin to clinical decisions.
UR - http://www.scopus.com/inward/record.url?scp=67449138837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67449138837&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-09-0099
DO - 10.1158/1078-0432.CCR-09-0099
M3 - Article
C2 - 19509151
AN - SCOPUS:67449138837
SN - 1078-0432
VL - 15
SP - 4157
EP - 4164
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -